Artificial Blood Substitutes Market – Patent landscape report, by source (human blood, animal blood, microorganism based recombinant Hb, synthetic polymers, stem cells) product type (PFCs, HBOCs), by application (Cardiovascular diseases, Malignant neoplasms, Injuries, Neonatal Conditions, Organ transplants, Maternal condition) by Patent Activities (patent categories and classification, patent landscape analysis, licensing and litigation) – Global Forecast, 2022 Executive Summary Human blood is a specialized bodily fluid that amounts to seven to eight percent of human body weight. This essential fluid performs the critical function of transporting oxygen and nutrients to the body cells and transporting back carbon dioxide, ammonia, and other waste products away from cells. Oxygen carrying capacity of human blood to lungs is attributed to the presence of red blood cells (RBCs) which are of utmost importance. Artificial blood substitutes are being researched and developed as alternatives for replacing RBCs for oxygen carrying capacity. Regular human blood has a shelf life of only 42 days which limits their utilization over more extended periods. This necessitates the development of blood substitutes which can be stored for longer durations. In addition, blood substitutes have universal compatibility, and therefore their application is not restricted by typing and cross-matching. Blood substitutes are extremely necessary in case of acute and chronic blood loss from injuries and accidents where a shortage of oxygen to cells affects the survival of patient by inflicting permanent damage to tissues. Blood substitutes market is categorized into two segments viz. Perfluorocarbon-based oxygen carriers (PFBOC), and Hemoglobin-based oxygen carriers (HBOC). PFBOCs are based on inert components which replace hydrogen with fluorine. HBOCs consists of hemoglobin derived products sourced from humans blood, bovine blood, microorganisms and transgenic animals. Companies like Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Nuvox Pharmaceuticals, Sanguine Inc., and Therapure Biopharma are the active palyers in the artificial blood products market. Global demand for blood is exponentially increasing which is exerting tremendous pressure on blood donation industry resulting into the illegal sale of human blood in the red market. To counter the above issue, there is a greater need for blood substitutes which can fulfill blood volume demands in short period. In this advancing world, we need artificial blood products to save precious human lives, and persistent research and innovation can only achieve the intended results.

$600.00 – $3,900.00Select options

Table of Content About Ahead Intel (Page no. – 1) Disclaimer (Page no. – 2) Executive Summary (Page no. – 7) 1. Introduction (Page no. – 8) 1.1. Study Goals And Objectives 1.2. Scope Of The Report 1.3. Market Estimation Methodology 1.4. Intended Audience 2. Technology Overview (Page no. – 10) $700.00Add to cart 2.1. Introduction To Blood Substitutes 2.2. Existing Blood Supply Constraints 2.3. Advances In Blood Transfusion Over The Years 2.4. Ideal Blood Substitutes 2.5. Benefits Of Artificial Blood Substitutes 3. Business Landscape And Forecast (Page no. – 19)

$700.00Add to cart 3.1. Market Impacting Factors 3.2. Market Size And Penetration 3.3. Market Segmentation By Source 3.3.1. Artificial Blood Substitutes From Human Blood 3.3.2. Artificial Blood Substitutes From Animal (Bovine And Transgenic) Blood 3.3.3. Artificial Blood From Microorganism Based Recombinant Hb 3.3.4. Artificial Blood From Synthetic Polymers 3.3.5. Artificial Blood From Stem Cells 3.4. Market Segmentation By Product Type 3.4.1. Hemoglobin-Based Oxygen Carriers (Hbocs) 3.4.2. Acellular Hbocs 3.4.3. Cellular Hbocs 3.4.4. Perfluorocarbon-Based Oxygen Carriers (Pfcs) 3.4.5. First Generation Of Pfcs 3.4.6. Second Generation Of Pfcs 3.4.7. Third Generation Of Pfcs 3.4.8. Comparative Analysis Of The Type Of Artificial Blood Substitutes 3.5. Market Segmentation By Application 3.5.1. Cardiovascular Diseases 3.5.2. Malignant Neoplasms 3.5.3. Injuries 3.5.4. Neonatal Conditions 3.5.5. Organ Transplants 3.5.6. Maternal Condition 3.5.7. Other Cases 3.6. Market Segmentation By Region 3.6.1. North America 3.6.2. Europe 3.6.3. Apac 3.6.4. Rest Of The World (Row) 4. Market Trends And Challenges (Page no. – 82)

$600.00Add to cart 4.1. Market Trends 4.2. Constraints In Development Of Artificial Blood Substitutes 5. Competitive Landscape (Page no. – 85)

$700.00Add to cart 5.1. Active Molecules’ Park Competence Alliance (Pam) 5.2. Alliance Pharmaceutical Corp 5.3. Baxter Healthcare Corporation 5.4. Fluoro2 Therapeutics, Inc 5.5. Hbo2 Therapeutics Llc 5.6. Hemarina Sa 5.7. Hemobiotech Inc 5.8. Kalocyte Inc 5.9. Northfield Laboratories Inc 5.10. Nuvox Pharma Llc 5.11. Opk Biotech, Llc 5.12. Prolong Pharmaceuticals, Llc 5.13. Sangart, Inc 5.14. Sanguine Corporation 5.15. Spheritech 5.16. Tenax Therapeutics Inc 5.17. Terumo Corporation 5.18. Therapure Biopharma Inc 6. Innovation Landscape (Page no. – 106)

$2,200.00Add to cart 6.1. Introduction 6.2. Search Strategy 6.3. Categories And CPC Classification 6.4. How Is The Innovation Activity Trend? 6.5. What Are The Key Grant Timelines? 6.6. Who Are The Leading Players? 6.6.1. Who Is Making Substantial Investment In The Technology? 6.6.2. Who Are The Key Inventors In The Domain? 6.6.3. Who Is More Active In R&D? Academia Or Corporate? 6.7. Which Are The Current Technological Focus Areas? 6.7.1. Which Substitute Type Is Gaining Momentum? 6.7.2. Which Sources Are Being Preferred For Developing Artificial Blood Substitute? 6.7.3. Which Application Areas Will Drive The Market? 6.7.4. Which Are The Key Geographies For Setting Up Innovation Centres? 6.7.5. Which Geographies Are Touted As Investment Goldmines? 6.8. How Is The Blood Substitute Technology Regulated? 7. Appendix (Page no. – 135) 7.1. Acronyms, Abbreviations, And Units 7.2. Methodology And Information Sources 7.3. Analyst Profile Table Of Tables Table 1 Average Number Of Blood Units Required For Each Case Table 2 Market Penetration Cases Based On A Set Of Assumptions Table 3 Acellular Hbocs Product Description Table 4 Cellular Hbocs Product Description Table 5 Indicative Pfc Composition Table 6 Ideal Characteristics Of Perfluorocarbons And Emulsifiers Used In Pfcs Table 7 Generations Of Pfcs Table 8 Other First-Generation Pfc Emulsions Researched And Developed Table 9 Comparative Study Of Second-Generation Pfcs Table 10: Pfcs Products And Status Table 11 Comparative Analysis Of Properties Of Donor Blood, Hbocs, And Pfc Emulsions Table 12 Global Potential Artificial Blood Market, By Application, Through 2027 ($ Millions) Table 13 Critical Blood Transfusion Statistics For North America Table 14 Potential Artificial Blood Market For North America, 2022 To 2027 (In $ Million) Table 15 Critical Blood Transfusion Statistics For Europe Table 16 Potential Artificial Blood Market For Europe, 2022 To 2027 (In $ Million) Table 17 Critical Blood Transfusion Statistics For Apac Table 18 Potential Artificial Blood Market For Apac, 2022 To 2027 (In $ Million) Table 19 Critical Blood Transfusion Statistics For North America, 2016-2017 Table 20 Potential Artificial Blood Market For Row, 2022 To 2027 (In $ Million) Table 21 Active Molecules’ Park Competence Alliance (Pam): Company And Product Snapshot Table 22 Alliance Pharmaceutical Corp.: Company And Product Snapshot Table 23 Baxter Healthcare Corporation: Company And Product Snapshot Table 24 Fluoro2 Therapeutics, Inc.: Company And Product Snapshot Table 25 Hbo2 Therapeutics Llc: Company And Product Snapshot Table 26 Hemarina Sa: Company And Product Snapshot Table 27 Hemobiotech, Inc.: Company And Product Snapshot Table 28 Kalocyte Inc.: Company And Product Snapshot Table 29 Northfield Laboratories Inc.: Company And Product Snapshot Table 30 Nuvox Pharma Llc: Company And Product Snapshot Table 31 Opk Biotech, Llc: Company And Product Snapshot Table 32 Prolong Pharmaceuticals, Llc: Company And Product Snapshot Table 33 Sangart, Inc.: Company And Product Snapshot Table 34 Sanguine Corporation: Company And Product Snapshot Table 35 Spheritech: Company And Product Snapshot Table 36 Tenax Therapeutics, Inc.: Company And Product Snapshot Table 37 Terumo Corporation: Company And Product Snapshot Table 38 Therapure Biopharma Inc.: Company And Product Snapshot Table 39 Top Inventors Vs. Priority Country Portfolio Table 40 Artificial Blood Substitutes Patent Categories Table 41 Level 2 And Level 3 Product Type Categories With The Number Of Patents Table 42 Patent Portfolio Of Top 20 Assignees Across Level 2 Product Type Segmentation Table 43 Level 2 Product Source Categories With The Number Of Patents Table 44 Patent Distribution Of Top 20 Companies Across Level 2 Product Source Categories Table 45 Number And Evolution Of Patent Families Per Office Of First Filling- Top 15 Table Of Figures Figure 1 Application Areas For Artificial Blood Substitutes Figure 2 Total Number Of Surgeries And Death Cases Globally From 2017 To 2027 Figure 3 Number Of Blood Units Transfused Globally In Millions (2017 To 2027) Figure 4 Global Potential For Artificial Blood Substitutes Market (In $Millions) For 2022-2027 Figure 5 Artificial Blood Substitute Market Segmentation By Source Figure 6 Artificial Blood Substitute Market Segmentation By Product Type Figure 7 Critical Issues With Free Hemoglobin Molecules In The Bloodstream Figure 8 Application Indication Of Artificial Blood Substitutes Figure 9 Global Potential Artificial Blood Market, By Application, 2022 To 2027 Figure 10 Potential Artificial Blood Market For North America, 2022 To 2027 (In $ Million) Figure 11 Potential Artificial Blood Market For Europe, 2022 To 2027 (In $ Million) Figure 12 Potential Artificial Blood Market For Apac, 2022 To 2027 (In $ Million) Figure 13 Potential Artificial Blood Market For Row, 2022 To 2027 (In $ Million) Figure 14 Constraints In The Development Of Artificial Blood Products Figure 15 Schematic Diagram To Represent Key Steps In Patent Analysis Process Figure 16 Overview Of Artificial Blood Substitutes Technology Figure 17 Top 10 Artificial Blood Substitutes Patents Classification Categories As Per CPC Figure 18: Global Artificial Blood Substitutes Patenting Activity Trend Figure 19: Global Artificial Blood Substitutes Patent Grant Time Figure 20: Top 15 Patent Assignees In The Artificial Blood Substitute Patent Landscape Figure 21: Trends For Patent Portfolio Size-Current Owner Wise Figure 22: Top 15 Influencers In Artificial Blood Substitutes Research Landscape Figure 23: Key Inventors In Artificial Blood Substitute Landscape Figure 24: Analysis Of Patent Applicant Profile Figure 25: Global Artificial Blood Substitute Patenting Trends Based On Application Areas (1997-2018) Figure 26: Major Offices Of First Fillings Linked To Their Region Figure 27: Geographic Map Of R&D In The Field Of Artificial Blood Substitute Technology Figure 28: Geographic Map Of Market Opportunities In Artificial Blood Substitute Technology Figure 29: Representation Of Market Opportunities Of Artificial Blood Substitute Patent Landscape

Analyst Review This report aims to present business and patent landscape for the emerging market of artificial blood substitutes. The objective is to analyze existing technologies and emerging trends in each aspect of the industry. The study provides information on the global supply and demand for human blood, the constraints associated with the supply, the market need to develop artificial blood substitutes, limitations associated with artificial blood substitute development. The report also covers the status of various Hemoglobin based oxygen carriers (HBOCs) and Perfluorocarbon based oxygen carrier (PFC) emulsions. Also, the study presents a detailed analysis of research activities in this industry along with significant patent data trends and analysis. Artificial blood products market has been analyzed based on various attributes such as source, type, and application areas. The report attempts to segment the market based on sources from which blood substitutes are derived, product features, technology and methodology used. Six potential application markets have been identified based on the possibility of replacing donor blood in critical medical treatments. Potential applications of the blood substitutes have been discussed, and market growth for each application segment have been predicted further for the period 2022 to 2027. Number of artificial blood units required for blood transfusion in each of the six categories of medical treatment cases have been assumed based on the current average number of donor blood units used for transfusion procedures in these categories. Two scenarios of market penetration have been estimated based on product acceptance. The global potential market is forecasted for 2022 and 2027 regarding volume and value for the two market penetration cases considering the total number of blood transfusions taking place globally and number of artificial blood units required for these procedures. The market data has been assessed and validated considering interrelated market attributes. Report will also focus on competitor landscape with product profiling, projected global potential market size for artificial blood substitutes regarding both volume and value for 2022 and 2027, forecasted market penetration scenarios including market impacting factors. In-depth company profiling of active as well as inactive companies and their products have been included in this report. Regional dynamics of the global artificial blood market and current trends within the industry have been deliberated in the report. In this report, the geographic regions considered for market analysis exclusively include: North America: United States, Mexico, Canada

Europe: U.K., Germany, Russia, Spain, France, Italy

Asia Pacific: China, India, Japan, Australia

Rest of the world: South Africa, Brazil $600.00 – $3,900.00Select options

Request a Sample

